Key opinion leaders and presenters offer their insight on the latest advances in the management of patients with multiple sclerosis at the 2022 Consortium of Multiple Sclerosis Centers annual meeting.
June 6th 2022
Jeffrey Cohen, MD, shared his perspective on the current use and study of stem cells for the treatment of multiple sclerosis, which he covered in the CMSC Presidential Lecture at the 2022 annual meeting.
June 7th 2022
Jeffrey Cohen, MD, spoke about the topic of his CMSC Presidential Lecture at the 2022 annual meeting, stem cell transplantation in multiple sclerosis, and what questions remain unanswered in this realm of treatment.
June 8th 2022
Daniel Kantor, MD, discussed his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis who are being treated with sphingosine 1 phosphate receptor modulators.
June 9th 2022
Daniel Kantor, MD, discussed the data from his presentation at the 2022 CMSC annual meeting on COVID-19 vaccine response in patients with multiple sclerosis, and what questions are still lingering among the clinical community.
June 10th 2022
Robert Fox, MD, shared the details of the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis, presented at the CMSC 2022 Annual Meeting.
June 11th 2022
Robert Fox, MD, offered perspective on data from the DISCO-MS study of disease-modifying therapy discontinuation in patients with multiple sclerosis and how it compares with day-to-day clinical practice.
June 12th 2022
Robert Fox, MD, who presented the DISCO-MS study results at the CMSC 2022 Annual Meeting, offered his closing thoughts on the data and the take-home messaging for clinicians.
AHS 2022: Top Interviews and Key Takeaways
ALS-Related Biomarkers Remain Unchanged With PrimeC Combination Treatment
Awareness of Botulinum Toxins in the Movement Disorder Landscape: Laxman Bahroo, DO
Pioneering Care for Autoimmune Disorders Through Research and Results: The Mayo Clinic Way